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Introduction
The cysteine-rich protein 2 has previously been suggested
as a novel target of PKG1. Cysteine-rich proteins (CRP)
are evolutionarily conserved proteins that define a subset
of zinc-binding LIM domain proteins. This family of LIM
domain proteins originally included three members
(CRP1, CRP2/SLIM, CRP3/MLP). Previously, a new mem-
ber of the CRP family was identified through a yeast two
hybrid screen using PKG1 as bait. This protein was ini-
tially named CRP2. Subsequently, based on structural and
sequence similarities, and because it is the product of a
distinct gene and not an ortholog of CRP2/smLIM this
new CRP2 was grouped into the CRP1, CRP2/SLIM,
CRP3/MLP subset of LIM domain proteins and is also
referred to as CRP4. CRP4 is expressed in laminas I and II
of the mouse spinal cord and is colocalized with PKG1
and the dorsal root ganglion (DRG) marker proteins cal-
citonin gene-related peptide, isolectin B4 and peripherin.
CRP4 is phosphorylated in a cGMP-dependent manner,
and its expression increases in the spinal cord and in
DRGs after noxious stimulation of a hindpaw. CRP4-/-
mice show increased nociceptive behavior in models of
inflammatory hyperalgesia compared to wild-type mice.
Intrathecal administration of cGMP analogs increases the
nociceptive behavior in wild-type but not in CRP4-/- mice,
indicating that the presence of CRP4 is important for
cGMP-mediated nociception. CRP4 has been suggested as
a new effector of PKG1-mediated spinal nociceptive
processing and point to an inhibitory role of CRP2 in the
generation of inflammatory pain.
Results
Here we show, that CRP4, apart from DRG neurons, is
predominantly expressed in vascular smooth muscle cells.
CRP4 is phosphorylated by PKG1 but not PKA in blood
vessels. Cyclic GMP/PKG-mediated relaxation is
enhanced in CRP4-/- small arteries, whereas cAMP-medi-
ated vasorelaxation is not affected. Consistently, long-
term radiotelemetric recordings reveal a decrease of mean
arterial pressure by 10 mmHg and an enhanced NO/
cGMP signaling in CRP4-/- mice. Western blotting analysis
show increased expression of soluble guanylyl cyclase
(sGC) in CRP4-/- vascular smooth muscle, whereas the
expression of PKG and its effectors is not altered. Two-
dimensional difference gel electrophoresis of the aortic
proteome reveal caldesmon, an actin and tropomyosin
binding protein, as well as vimentin and zyxin to be up-
regulated whereas vinculin and smooth muscle protein
SM22 are down-regulated at their expression level. An
observed increase of adhesion of CRP4-/- aortic cells under
basal and cGMP stimulated conditions may be a conse-
quence of up-regulated cytoskeletal proteins such as cald-
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esmon and zyxin. In agreement with increased adhesion
of vascular smooth muscle cells, magnet resonance imag-
ing and histological stainings demonstrate a decreased
vessel wall thickness after injury of the carotid artery in
CRP4-/- mice.
Conclusion
Our findings elucidate CRP4 as new and specific in vivo
effector of the vascular NO/cGMP/PKG signaling and pro-
vide some new insights in the functional relevance of this
protein.